menu
    • menu
    [{"orgOrder":0,"company":"Biomed Industries","sponsor":"Bioneurals","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NA-931","moa":"\nGCGR\/GIPR\/GLP-1R\/IGF-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biomed Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomed Industries \/ Bioneurals","highestDevelopmentStatusID":"8","companyTruncated":"Biomed Industries \/ Bioneurals"},{"orgOrder":0,"company":"Biomed Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NA-931","moa":"\nGCGR\/GIPR\/GLP-1R\/IGF-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biomed Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomed Industries \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomed Industries \/ Inapplicable"},{"orgOrder":0,"company":"Biomed Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NA-931","moa":"\nGCGR\/GIPR\/GLP-1R\/IGF-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biomed Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomed Industries \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomed Industries \/ Inapplicable"},{"orgOrder":0,"company":"Empros Pharma","sponsor":"CTC Clinical Trial Consultants","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Orlistat","moa":"Pancreatic lipase | Gastric lipase","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Empros Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule, Prolonged Release","sponsorNew":"Empros Pharma \/ CTC Clinical Trial Consultants","highestDevelopmentStatusID":"8","companyTruncated":"Empros Pharma \/ CTC Clinical Trial Consultants"},{"orgOrder":0,"company":"Empros Pharma","sponsor":"CTC Clinical Trial Consultants","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Orlistat","moa":"Pancreatic lipase | Gastric lipase","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Empros Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule, Prolonged Release","sponsorNew":"Empros Pharma \/ CTC Clinical Trial Consultants","highestDevelopmentStatusID":"8","companyTruncated":"Empros Pharma \/ CTC Clinical Trial Consultants"},{"orgOrder":0,"company":"S1 Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"S1B-509","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"S1 Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"S1 Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"S1 Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Scotmann Pharmaceuticals","sponsor":"Rawalpindi Medical College","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"PAKISTAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Sunnyd Stat","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scotmann Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Scotmann Pharmaceuticals \/ Rawalpindi Medical College","highestDevelopmentStatusID":"8","companyTruncated":"Scotmann Pharmaceuticals \/ Rawalpindi Medical College"},{"orgOrder":0,"company":"Rose Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ROSE-010","moa":"5-HT4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Rose Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rose Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rose Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Children's Discovery Institute | Polaris Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegargiminase","moa":"L-arginine","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ Children's Discovery Institute | Polaris Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Children's Discovery Institute | Polaris Pharmaceuticals"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Pindolol","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Actimed Therapeutics \/ Mankind Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Mankind Pharma"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Pindolol","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Actimed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Bimagrumab","moa":"||Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":1.9299999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":1.9299999999999999,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Eli Lilly"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Bimagrumab","moa":"||Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":1.9299999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":1.9299999999999999,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Eli Lilly"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"||Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nimacimab","moa":"Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nimacimab","moa":"Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nimacimab","moa":"Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Arecor","sponsor":"Skye Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"Nimacimab","moa":"||Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Skye Bioscience","highestDevelopmentStatusID":"8","companyTruncated":"Arecor \/ Skye Bioscience"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Beacon Biosignals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Nimacimab","moa":"Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Skye Bioscience \/ Beacon Biosignals","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Beacon Biosignals"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nimacimab","moa":"Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"||Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Versanis Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Glucose","moa":"Blood glucose level","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aphaia Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GSBR-1290","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Structure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Structure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GSBR-1290","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Structure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Structure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"TERN-601","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Monlunabant","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"RGT001-075","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Regor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RGT001-075","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Regor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Glyscend Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"GLY-200","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Glyscend Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glyscend Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Glyscend Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Glyscend Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"GLY-200","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Glyscend Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glyscend Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Glyscend Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Miricorilant","moa":"glucocorticoid receptor antagonists (not glucocorticoids)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tesofensine","moa":"Monoamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Shandong Suncadia Medicine Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HRS-7535","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Shandong Suncadia Medicine Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shandong Suncadia Medicine Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shandong Suncadia Medicine Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"MindRank","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MDR-001","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"MindRank","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MindRank \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindRank \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Miricorilant","moa":"glucocorticoid receptor antagonists (not glucocorticoids)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Miricorilant","moa":"glucocorticoid receptor antagonists (not glucocorticoids)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Chengdu DIAO Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"DA-302168S","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Chengdu DIAO Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chengdu DIAO Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Chengdu DIAO Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Nabilone","moa":"Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centre for Addiction and Mental Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Danuglipron","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"University of California, San Diego","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Denatonium Acetate","moa":"TAS2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aardvark Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aardvark Therapeutics \/ University of California, San Diego","highestDevelopmentStatusID":"8","companyTruncated":"Aardvark Therapeutics \/ University of California, San Diego"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"University of California, San Diego","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Denatonium Acetate","moa":"TAS2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aardvark Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aardvark Therapeutics \/ University of California, San Diego","highestDevelopmentStatusID":"8","companyTruncated":"Aardvark Therapeutics \/ University of California, San Diego"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diazoxide","moa":"ABCC8(SUR1)\/KCNJ11(KIR6.2)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"INV-202","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inversago Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kallyope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"K-757","moa":"Nutrient receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Kallyope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kallyope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kallyope \/ Inapplicable"},{"orgOrder":0,"company":"LG Chem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LB54640","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LB54640","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azelaprag","moa":"Apelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioAge Labs \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Eli Lilly"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"LG Chem","sponsor":"Rhythm Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Bivamelagon","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"LG Chem","amount2":0.31,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.31,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Rhythm Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ Rhythm Pharmaceuticals"},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dextrose","moa":"Blood glucose level","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aphaia Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dextrose","moa":"Blood glucose level","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aphaia Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"RGT-075","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Regor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RGT-075","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Regor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bivamelagon","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kallyope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"K-757","moa":"||Nutrient receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Kallyope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kallyope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kallyope \/ Inapplicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azelaprag","moa":"||Apelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioAge Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Inapplicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azelaprag","moa":"||Apelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioAge Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tisolagiline","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"IPMC","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Tisolagiline","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scilex Pharmaceuticals \/ IPMC","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pharmaceuticals \/ IPMC"},{"orgOrder":0,"company":"Eccogene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"ECC5004","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eccogene","amount2":2.0099999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2.0099999999999998,"dosageForm":"Tablet","sponsorNew":"Eccogene \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Eccogene \/ AstraZeneca"},{"orgOrder":0,"company":"Vincentage Pharma","sponsor":"Corxel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"VCT220","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Vincentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vincentage Pharma \/ Corxel Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Vincentage Pharma \/ Corxel Pharmaceuticals"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Neurobiogen","sponsor":"Scilex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Tisolagiline","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Neurobiogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurobiogen \/ Scilex Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Neurobiogen \/ Scilex Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Danuglipron","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Danuglipron","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Response Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"RDX-002","moa":"MTP","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Response Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Response Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Response Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"HU6","moa":"Sugar oxidation","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Rivus Pharmaceuticals \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Pharmaceuticals \/ RA Capital Management"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"TNF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"TNF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TNF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TNF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"HRS9531","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CordenPharma","sponsor":"Viking Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide","year":"2025","type":"Partnership","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"CordenPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CordenPharma \/ Viking Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"CordenPharma \/ Viking Therapeutics"},{"orgOrder":0,"company":"Glaceum","sponsor":"Gangnam Severance Hospital | Seoul National University Bundang Hospital | Korea University Anam Hospital | Seoul National University Hospital | SMG-SNU Boramae Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HSG4112","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Glaceum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glaceum \/ Gangnam Severance Hospital | Seoul National University Bundang Hospital | Korea University Anam Hospital | Seoul National University Hospital | SMG-SNU Boramae Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Glaceum \/ Gangnam Severance Hospital | Seoul National University Bundang Hospital | Korea University Anam Hospital | Seoul National University Hospital | SMG-SNU Boramae Medical Center"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"S309309","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AZD5004","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LY3549492","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GSBR-1290","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Structure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Structure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GSBR-1290","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Structure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Structure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GSBR-1290","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Structure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Structure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Shandong Suncadia Medicine Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HRS-7535","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Shandong Suncadia Medicine Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shandong Suncadia Medicine Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shandong Suncadia Medicine Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"MindRank","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"MDR-001","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"MindRank","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MindRank \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindRank \/ Inapplicable"},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"NovaClin Medical Research Center S.R.L | ACC GmbH Analytical Clinical Concepts | SC Bioclinica SA | Galephar Pharmaceutical Research (PR), Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Glucose","moa":"Blood glucose level","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aphaia Pharma \/ NovaClin Medical Research Center S.R.L | ACC GmbH Analytical Clinical Concepts | SC Bioclinica SA | Galephar Pharmaceutical Research (PR), Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pharma \/ NovaClin Medical Research Center S.R.L | ACC GmbH Analytical Clinical Concepts | SC Bioclinica SA | Galephar Pharmaceutical Research (PR), Inc."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Monlunabant","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TERN-601","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TERN-601","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Miricorilant","moa":"glucocorticoid receptor antagonists (not glucocorticoids)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MindRank","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MDR-001","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"MindRank","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MindRank \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MindRank \/ Inapplicable"},{"orgOrder":0,"company":"Chengdu DIAO Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DA-302168S","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Chengdu DIAO Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chengdu DIAO Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Chengdu DIAO Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Chengdu DIAO Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DA-302168S","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Chengdu DIAO Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chengdu DIAO Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Chengdu DIAO Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Chengdu DIAO Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DA-302168S","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Chengdu DIAO Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chengdu DIAO Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Chengdu DIAO Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Danuglipron","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HU6","moa":"Sugar oxidation","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rivus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Kallyope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"K-757","moa":"Nutrient receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Kallyope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kallyope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kallyope \/ Inapplicable"},{"orgOrder":0,"company":"Kallyope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"K-757","moa":"Nutrient receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Kallyope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kallyope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kallyope \/ Inapplicable"},{"orgOrder":0,"company":"Kallyope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"K-757","moa":"Nutrient receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Kallyope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kallyope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kallyope \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Danuglipron","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Danuglipron","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"ATLAS PHARMS LLC","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biophytis","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ ATLAS PHARMS LLC","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ ATLAS PHARMS LLC"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Eccogene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"ECC5004","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eccogene","amount2":2.0099999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2.0099999999999998,"dosageForm":"Tablet","sponsorNew":"Eccogene \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Eccogene \/ AstraZeneca"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Danuglipron","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Glaceum","sponsor":"Kyungpook National University Hospital | Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HSG4112","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Glaceum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glaceum \/ Kyungpook National University Hospital | Seoul National University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Glaceum \/ Kyungpook National University Hospital | Seoul National University Hospital"},{"orgOrder":0,"company":"Glaceum","sponsor":"Seoul National University Hospital | Kyungpook National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HSG4112","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Glaceum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glaceum \/ Seoul National University Hospital | Kyungpook National University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Glaceum \/ Seoul National University Hospital | Kyungpook National University Hospital"},{"orgOrder":0,"company":"Glaceum","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HSG4112","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Glaceum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glaceum \/ Seoul National University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Glaceum \/ Seoul National University Hospital"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"S309309","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Glaceum","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HSG4112","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Glaceum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glaceum \/ Seoul National University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Glaceum \/ Seoul National University Hospital"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NNC0487-0111","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"S309309","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NNC0487-0111","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NNC0487-0111","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Raymond James & Associates, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Enobosarm","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Veru \/ Raymond James & Associates, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Raymond James & Associates, Inc."},{"orgOrder":0,"company":"Veru","sponsor":"Raymond James & Associates, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Enobosarm","moa":"||Androgen Receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Veru \/ Raymond James & Associates, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Raymond James & Associates, Inc."},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Azelaprag","moa":"||Apelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioAge Labs \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Eli Lilly"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series D Financing","leadProduct":"Azelaprag","moa":"||Apelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.17000000000000001,"dosageForm":"Capsule","sponsorNew":"BioAge Labs \/ Sofinnova Investments","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Sofinnova Investments"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Retatrutide","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"BrightGene Bio-Medical Technology Co.,Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BGM0504","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BrightGene Bio-Medical Technology Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BrightGene Bio-Medical Technology Co.,Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BrightGene Bio-Medical Technology Co.,Ltd \/ Inapplicable"},{"orgOrder":0,"company":"BrightGene Bio-Medical Technology Co.,Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BGM0504","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BrightGene Bio-Medical Technology Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BrightGene Bio-Medical Technology Co.,Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BrightGene Bio-Medical Technology Co.,Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Public Offering","leadProduct":"Bremelanotide Acetate","moa":"||Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Alliance Global Partners"},{"orgOrder":0,"company":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","sponsor":"Shanghai Jiaotong University Affiliated Sixth People's Hospital | Beijing Friendship Hospital | Jinan Central Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efsubaglutide Alfa","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ Shanghai Jiaotong University Affiliated Sixth People's Hospital | Beijing Friendship Hospital | Jinan Central Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ Shanghai Jiaotong University Affiliated Sixth People's Hospital | Beijing Friendship Hospital | Jinan Central Hospital"},{"orgOrder":0,"company":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Efsubaglutide Alfa","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Fleroxacin","moa":"antibacterials (quinolone derivatives)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Raziel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Raziel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Metsera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"MET097","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metsera \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ Inapplicable"},{"orgOrder":0,"company":"Metsera","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"MET097","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.32000000000000001,"dosageForm":"Injection","sponsorNew":"Metsera \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ BofA Securities"},{"orgOrder":0,"company":"Metsera","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"MET097","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0.32000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.32000000000000001,"dosageForm":"Injection","sponsorNew":"Metsera \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ BofA Securities"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"10xbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polidocanol","moa":"Endothelium of blood vessels (Endothelium)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"10xbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"10xbio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"10xbio \/ Inapplicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"ALT-801","moa":"Cellular tumor antigen p53 (TP53)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"CT-868","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmot Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carmot Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"CT-388","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmot Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Carmot Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"AZD6234","moa":"AMYR","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"CT-388","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmot Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Carmot Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Parexel"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zealand Pharma \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Parexel"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Bofanglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Bofanglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Goldman Sachs International","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Dapiglutide","moa":"GLP-1R\/GLP-2R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0.90000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.90000000000000002,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Goldman Sachs International","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Goldman Sachs International"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Goldman Sachs International","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Dapiglutide","moa":"GLP-1R\/GLP-2R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":1,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.90000000000000002,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Goldman Sachs International","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Goldman Sachs International"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Dapiglutide","moa":"GLP-1R\/GLP-2R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Dapiglutide","moa":"GLP-1R\/GLP-2R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"The United Laboratories","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"HONG KONG","productType":"Peptide","year":"2025","type":"Licensing Agreement","leadProduct":"UBT251","moa":"GLP-1\/GIP\/Glucagon receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"The United Laboratories","amount2":2,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2,"dosageForm":"Injection","sponsorNew":"The United Laboratories \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"The United Laboratories \/ Novo Nordisk"},{"orgOrder":0,"company":"Metsera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"MET-097i","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Metsera \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Mifomelatide","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MBL949","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NNC0487-0111","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NNC0519-0130","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Chia Tai Innovative Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CPX101","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Chia Tai Innovative Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Innovative Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Chia Tai Innovative Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AZD9550","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Hangzhou Zhongmei Huadong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HDM1005","moa":"HDM allergens","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Hangzhou Zhongmei Huadong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Metsera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"MET097","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Metsera \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ Inapplicable"},{"orgOrder":0,"company":"Metsera","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"MET-097i","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Metsera \/ Altasciences Company Inc","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Metsera","sponsor":"Wellington Management","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Series B Financing","leadProduct":"MET-097i","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0.22,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.22,"dosageForm":"Injection","sponsorNew":"Metsera \/ Wellington Management","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ Wellington Management"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Retatrutide","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Retatrutide","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"BrightGene Bio-Medical Technology Co.,Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BGM0504","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BrightGene Bio-Medical Technology Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BrightGene Bio-Medical Technology Co.,Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BrightGene Bio-Medical Technology Co.,Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||Melanocortin receptor 4","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Profil Institut f\u00fcr Stoffwechselforschung GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Dapiglutide","moa":"GLP-1R\/GLP-2R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zealand Pharma \/ Profil Institut f\u00fcr Stoffwechselforschung GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Profil Institut f\u00fcr Stoffwechselforschung GmbH"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"CT-388","moa":"Gastric inhibitory polypeptide receptor (GIPR)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Carmot Therapeutics","amount2":3.1000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":3.1000000000000001,"dosageForm":"Injection","sponsorNew":"Carmot Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Carmot Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Dapiglutide","moa":"GLP-1R\/GLP-2R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Beijing QL Biopharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ZT002","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Beijing QL Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing QL Biopharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beijing QL Biopharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chia Tai Innovative Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CPX101","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Chia Tai Innovative Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Innovative Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Chia Tai Innovative Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Hangzhou Zhongmei Huadong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HDM1005","moa":"HDM allergens","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Hangzhou Zhongmei Huadong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Hangzhou Zhongmei Huadong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HDM1005","moa":"HDM allergens","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Hangzhou Zhongmei Huadong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NNC0519-0130","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NNC0519-0130","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Tonghua Dongbao Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"THDBH120","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Tonghua Dongbao Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonghua Dongbao Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonghua Dongbao Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Collaboration","leadProduct":"Petrelintide","moa":"||GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":5.2999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":5.2999999999999998,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"BI456906","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Versanis Bio","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Versanis Bio","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Versanis Bio"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Trevogrumab","moa":"Growth\/differentiation factor 8","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nimacimab","moa":"Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"Activin receptor type-2B","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nimacimab","moa":"Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Immunis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"IMM01-STEM","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Immunis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunis \/ Inapplicable"},{"orgOrder":0,"company":"KGK Science","sponsor":"InterHealth Nutraceuticals, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"7-Keto","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KGK Science \/ InterHealth Nutraceuticals, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"KGK Science \/ InterHealth Nutraceuticals, Inc."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Raziel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Raziel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APHD-012","moa":"Blood glucose level","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aphaia Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Neurogastrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NG101","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Neurogastrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurogastrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurogastrx \/ Inapplicable"},{"orgOrder":0,"company":"Response Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RDX-002","moa":"MTP","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Response Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Response Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Response Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shandong Suncadia Medicine Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HRS-7535","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Shandong Suncadia Medicine Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shandong Suncadia Medicine Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shandong Suncadia Medicine Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Metsera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MET097","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metsera \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ Inapplicable"},{"orgOrder":0,"company":"Zomagen Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"VTX3232","moa":"NLRP3","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zomagen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zomagen Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zomagen Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"S-Pindolol Benzoate","moa":"\n5-HT1A receptor\/Beta-adrenoceptors\/Beta2-adrenergic receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Mankind Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Mankind Pharma"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PH284","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Green Cross Well-being","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BST204","moa":"IL-6 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Green Cross Well-being","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Green Cross Well-being \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Green Cross Well-being \/ Inapplicable"},{"orgOrder":0,"company":"Lipidio Pharmaceuticals","sponsor":"Maxim Merchant Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"GDD3898","moa":"SCD1","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Lipidio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipidio Pharmaceuticals \/ Maxim Merchant Capital","highestDevelopmentStatusID":"8","companyTruncated":"Lipidio Pharmaceuticals \/ Maxim Merchant Capital"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"CT-868","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carmot Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Carmot Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Sciwind Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"XW003","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sciwind Biosciences \/ Sciwind Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ Sciwind Biosciences"},{"orgOrder":0,"company":"University Hospital Gentofte, Copenhagen","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Dapiglutide","moa":"GLP-1R\/GLP-2R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"University Hospital Gentofte, Copenhagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Gentofte, Copenhagen \/ Zealand Pharma","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital Gentofte, Copenhagen \/ Zealand Pharma"},{"orgOrder":0,"company":"Stanford University","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford University \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Stanford University \/ Eli Lilly"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"HS-20094","moa":"GLP-1\/GIP receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hansoh Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johns Hopkins University \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Johns Hopkins University \/ Eli Lilly"},{"orgOrder":0,"company":"Indonesia University","sponsor":"Medika Natura","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Labisia Pumila Aqueous Ethanolic Standardized Extract","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Indonesia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indonesia University \/ Medika Natura","highestDevelopmentStatusID":"8","companyTruncated":"Indonesia University \/ Medika Natura"},{"orgOrder":0,"company":"LALLEMAND HEALTH SOLUTIONS","sponsor":"Centre de recherche en nutrition humaine de Rh\u00f4ne-Alpes","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"LALLEMAND HEALTH SOLUTIONS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LALLEMAND HEALTH SOLUTIONS \/ Centre de recherche en nutrition humaine de Rh\u00f4ne-Alpes","highestDevelopmentStatusID":"8","companyTruncated":"LALLEMAND HEALTH SOLUTIONS \/ Centre de recherche en nutrition humaine de Rh\u00f4ne-Alpes"},{"orgOrder":0,"company":"Oranda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"IRELAND","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Oranda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oranda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oranda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"10xbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"XB-101","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"10xbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"10xbio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"10xbio \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SHR20004","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Inapplicable"},{"orgOrder":0,"company":"10xbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"XB-101","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"10xbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"10xbio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"10xbio \/ Inapplicable"},{"orgOrder":0,"company":"AMIpharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Polyene Phosphatidylcholine","moa":"Homeostasis","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"AMIpharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Solution","sponsorNew":"AMIpharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AMIpharm \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Mazdutide","moa":"Glucagon receptor (GCGR)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Mazdutide","moa":"Glucagon receptor (GCGR)","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LY3841136","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LY3841136","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PF-07976016","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RO7204239","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Raziel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Raziel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Raziel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Raziel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"BI456906","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"BI456906","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Verdiva Bio","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2025","type":"Licensing Agreement","leadProduct":"Ecnoglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":2.4700000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2.4700000000000002,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ Verdiva Bio","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ Verdiva Bio"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Danuglipron","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LY3841136","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NNC0487-0111","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"AMIpharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Polyene Phosphatidylcholine","moa":"Homeostasis","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"AMIpharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMIpharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AMIpharm \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LY3841136","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"IDG Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2021","type":"Series C Financing","leadProduct":"Ecnoglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ IDG Capital","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ IDG Capital"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"||GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nimacimab","moa":"||Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Empros Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Acarbose","moa":"LIPF|MGAM","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Empros Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Empros Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Empros Pharma \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RO7795081","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LY6249492","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"MindRank","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"MDR-001","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"MindRank","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MindRank \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MindRank \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"AZD6234","moa":"AMYR","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"The United Bio-Technology (Hengqin) Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"UBT251","moa":"GLP-1|GIP|Glucagon receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"The United Bio-Technology (Hengqin) Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"The United Bio-Technology (Hengqin) Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"The United Bio-Technology (Hengqin) Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Beijing QL Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ZT002","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Beijing QL Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing QL Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing QL Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Tonghua Dongbao Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"THDBH120","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Tonghua Dongbao Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonghua Dongbao Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonghua Dongbao Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"XW003","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"XW003","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sciwind Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"HS-20094","moa":"GLP-1|GIP receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Efsubaglutide Alfa","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"SCIRENT Clinical Research and Science d.o.o.","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"(S)-Pindolol Benzoate","moa":"5-HT1A receptor | beta-adrenoceptors | beta 2-adrenergic receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Actimed Therapeutics \/ SCIRENT Clinical Research and Science d.o.o.","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ SCIRENT Clinical Research and Science d.o.o."},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"APHD-012","moa":"Blood glucose level","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aphaia Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Neurobiogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tisolagiline","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Neurobiogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurobiogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neurobiogen \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ASC30","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Graviton Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"GV101","moa":"ROCK2","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Graviton Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Graviton Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Graviton Bioscience \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Allergan Aesthetics

                            U.S.A
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deoxycholic Acid

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 10, 2014

                            Lead Product(s) : Deoxycholic Acid

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie CB

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Raziel Therapeutics

                            Israel arrow
                            Vitafoods
                            Not Confirmed

                            Raziel Therapeutics

                            Israel arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RZL-012

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : 365mc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            365mc and Raziel Announce Collaboration to Develop RZL-012 in South Korea

                            Details : Through this collaboration, the two companies will jointly design and implement the Phase 3 clinical strategy for RZL-012 in South Korea.

                            Product Name : RZL-012

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 15, 2025

                            Lead Product(s) : RZL-012

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : 365mc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Neurobiogen

                            South Korea arrow
                            Vitafoods
                            Not Confirmed

                            Neurobiogen

                            South Korea arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tisolagiline

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Efficacy and Safety of KDS2010 in Overweight or Obese Patients

                            Details : Tisolagiline is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Overweight.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 06, 2025

                            Lead Product(s) : Tisolagiline

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ascletis Pharma

                            China arrow
                            Vitafoods
                            Not Confirmed

                            Ascletis Pharma

                            China arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASC30

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Efficacy, and Tolerability In Overweight/Obese Participants with Comorbidities

                            Details : ASC30 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Overweight.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 04, 2025

                            Lead Product(s) : ASC30

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Empros Pharma

                            Country arrow
                            Vitafoods
                            Not Confirmed

                            Empros Pharma

                            Country arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acarbose

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial with EMP16 in Preparation for Late Phase Studies

                            Details : EMP16 (Acarbose) is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Obesity.

                            Product Name : EMP16

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 28, 2025

                            Lead Product(s) : Acarbose

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Graviton Bioscience

                            U.S.A arrow
                            Vitafoods
                            Not Confirmed

                            Graviton Bioscience

                            U.S.A arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GV101

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GV101 in Healthy Obese Participants

                            Details : GV101 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Overweight.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 20, 2025

                            Lead Product(s) : GV101

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Arecor

                            United Kingdom arrow
                            Vitafoods
                            Not Confirmed

                            Arecor

                            United Kingdom arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nimacimab,Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Skye Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Skye Bioscience Partners with Arecor to Improve Obesity Drug Nimacimab

                            Details : Under the agreement, Skye will fund Arecor’s development activities with the option to license rights to the new formulation of nimacimab and to further develop & commercialize the product.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            May 19, 2025

                            Lead Product(s) : Nimacimab,Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Skye Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Caliway Biopharmaceuticals

                            Taiwan arrow
                            Vitafoods
                            Not Confirmed

                            Caliway Biopharmaceuticals

                            Taiwan arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CBL-514

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Caliway Holds Successful EOP2 Meeting With FDA for CBL-514 Fat Reduction

                            Details : CBL-514 is a potentially first-in-class small-molecule drug, is an injection lipolysis drug that can induce adipocytes apoptosis and lipolysis. It is being evaluated for subcutaneous fat reduction.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 14, 2025

                            Lead Product(s) : CBL-514

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            F. Hoffmann-La Roche

                            Switzerland arrow
                            Vitafoods
                            Not Confirmed

                            F. Hoffmann-La Roche

                            Switzerland arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RO7204239

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 11, 2025

                            Lead Product(s) : RO7204239

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Zealand Pharma

                            Denmark arrow
                            Vitafoods
                            Not Confirmed

                            Zealand Pharma

                            Denmark arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Petrelintide

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zealand Enrolls First in ZUPREME-2 Trial of Petrelintide for Obesity And T2D

                            Details : ZP8396 (petrelintide) is a long-acting amylin analog suitable for once-weekly subcutaneous administration that has been designed for the treatment of obesity.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            April 24, 2025

                            Lead Product(s) : Petrelintide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth